A Phase 1, Open Label, Multiple Dose Study Of The Effect Of PF-04171327 On Midazolam Pharmacokinetics In Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 01 Apr 2018
At a glance
- Drugs Fosdagrocorat (Primary) ; Midazolam
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 01 Apr 2018 Results (n=12) assessing the effects of multiple doses of fosdagrocorat on the blood levels (pharmacokinetics) of midazolam, were published in the Clinical Pharmacology in Drug Development.
- 11 Dec 2009 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
- 11 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.